MUSK and myasthenia gravis: Previous studies using DSG3-CAART or MuSK-CAART have demonstrated the preclinical feasibility and safety of antigen-specific B cell depletion in in vitro and in vivo models (10–12), leading to phase 1 clinical trials in mucosal pemphigus vulgaris and MuSK-MG.